A01 Gastric Cancer Pre-Screener Project: Development of a Comprehensive Gastric Cancer Risk Questionnaire. Haejin In, Marisa Langdon-Embry, Judith Wylie-Rosett, Bruce Rapkin.

A02 Risk models for cancer screening cohorts assembled from electronic health records: Application to calculating risks that underlie current cervical cancer screening guidelines. Li C Cheung, Qing Pan, Noorie Hyun, Mark Schiffman, Barbara Fetterman, Philip E Castle, Thomas Lorey, Hormuzd A Katki.

A03 Risk prediction for gastric cancer using the GWAS-identified SNPs, Helicobacter pylori infection and lifestyle-related risk factors in a Japanese population. Hidemi Ito, Isao Oze, Keitaro Matsuo.

A04 Breast cancer risks associated with predisposition gene mutations identified by clinical genetic testing of 64,000 breast cancer patients. Fergus J Couch, Chunling Hu, Hermela Shimelis, Jenna Lilyquist, Margaret Akinhanmi, Rachel McFarland, Holly LaDuca, David Goldgar, Jill S Dolinsky.


A06 Association of environmental risk factors, family history, and polygenic risk scores with chronic lymphocytic leukemia. Geffen Kleinstern, Dennis Robinson, Tim G Call, Mark Liebow, Silvia de Sanjosé, Yolanda Benavente, James R. Cerhan, Susan L Slager.


A09 A next generation sequencing based microsatellite instability assay suitable for routine risk stratification in colorectal cancer. Ghanim Alhilal, Lisa Redford, angel alonso, sira moreno, Mark
Arends, Anca Oniscu, Ottilia O’Brien, Stephanie Needham, John Burn, Michael Jackson, Mauro santibanez-koref.


A12 Urinary levels of PGE-M and estrogens are independently associated with postmenopausal breast cancer risk. Sangmi Kim, Jeff Campbell, Wonsuk Yoo, Jack A Taylor, Dale P Sandler.


A14 Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Mathew F. Buas, Haiwei Gu, Danijel Djukovic, Jianguang Zhu, Lynn Onstad, Brian Reid, Daniel Raftery, Thomas L. Vaughan.


A17 ANGPTL1 Antagonizes MET Receptor Activity to Repress Sorafenib Resistance and Cancer Stemness in Hepatocellular Carcinoma Cells. Jui-Ti Ma, Jen-Liang Su.

A18, PR06 Using frailty models to improve familial cancer risk prediction. Theodore Huang, Danielle Braun, Malka Gorfine, Giovanni Parmigiani.

A19 Neuroleptics in Breast Cancer. AN Johnston, Sonia Garcia, Sarah Hein, Wen Bu, Yi Li.

A20 Impact of radiochemotherapy in terms of host to microbiome interactions. Susan Haag, Emmanuel Menashi.


A23 Plasma Osteoprotegerin and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Leonardo Salmena, Lovisa Oden, Shana Kim, Mohammad Akbari, Ping Sun, Steven Narod, Joanne Kotsopoulos.

A24 BRM polymorphisms, part of a novel epigenetic mechanism, are predictive of cancer risk and clinic outcome in multiple cancer types. Suhdir Rai, Jennifer Wang, Kitman Wong, Xiaoping Qiu, Geoff Liu, David Reisman.


A28 Risk model for clinical management of HPV-infected women. Maria Demarco, Noorie Hyun, Hormuzd Katki, Brian Befano, Li Cheung, Tina R Raine-Bennett, Barbara Fetterman, Thomas Lorey, Nancy Poitras, Julia C Gage, Phillip E Castle, Nicolas Wentzensen, Mark Schiffman.

A29 Mathematical models are not the be-all and end-all for breast cancer risk assessment. Freya Schnabel, Jennifer Chun, Shira Schwartz, Amber Guth, Deborah Axelrod, Richard Shapiro, Karen Hiotis, Julia Smith.

Poster Session B
Friday, November 18
1:00 p.m. -3:30 p.m.
Ballroom D


B03 mtDNA gene variants appear to modify ovarian cancer risk in BRCA1 carriers. Catherine M Phelan, Daniel Barrowdale, Susan J Ramus, Fergus Couch, Paul PD Pharoah, Georgia Chenevix-Trench.

B04 Development of a comprehensive colorectal cancer risk prediction tool (CRiPT) incorporating known and unknown major genes and polygenes. Aung Ko Win, Mark A Jenkins, James G Dowty, Antonis C Antoniou, Andrew Lee, Yingye Zheng, Noralane M Lindor, Polly A Newcomb, John L Hopper, Robert J MacInnis.

B05 Effect of β-glucan on immunomodulatory activity in RAW264.7 cells. Eun Young Choi, So Hui Choe, Jin Yi Hyeon, In Soon Choi.


B07 The atopic dermatitis inhibitory effects of β-glucan and Lactobacillus plantarum. In Sung Kim, Jeong A Kim, Da Yoon Yu, Jong Min Lim, Jae Young Kim, In Soon Choi, Kwang Keun Cho.

B09 Serum vitamin D levels in breast cancer patients to assess its risk prediction to improve health. Vinit Mehrotra, Ashutosh Sharma.


B13 Adherence to cancer-specific prevention recommendations reduces risk of cancer in


B15 Communicating information about personalised genomic risk of melanoma to family, friends and health professionals. Anne E Cust, Amelia K Smit, David Espinoza, Keogh Louise, Phyllis N Butow, Kate Dunlop, Judy Kirk, Ainsley J Newson.

B16 Development of breast cancer risk prediction for the UK population using the UK Biobank dataset. Kawthar Alajmi, Artitaya Lophatananon, Kenneth Muir.


B19 Effect of cancer risk and patient preferences on net benefit of lung cancer screening: A Personalized Lung Cancer Screening Model. Pianpian Cao, Tanner Caverly, Rodney Hayward, Rafael Meza.


B21 The study of β-glucan on the Release of Nitric Oxide by Macrophages Stimulated with Lipopolysaccharide. Kwang Keun Cho.

B22 Expression of Sp1-modulated SOD2 in glioblastoma multiforme as the indicator of acquired temozolomide resistance and the worse disease course. Kwang-Yu Chang, Wen-Chang Chang, jian-Ying Chuang.

B23 Detection of Susceptibility to Childhood Acute Lymphoblastic Leukemia (ALL). Cameron K Tebbi.


B27 Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes. Lusine Yaghjian, Rulla Tamimi, Kimberly Bertrand, Christopher G Scott, Matthew R Jensen, Shane Pankratz, Kathleen Brandt, Daniel Visscher, Aaron Norman, Fergus Cough, John Shepherd, Bo Fan, Yunn-Yi Chen, Lin Ma, Andrew H Beck, Steven R Cummings, Karla Kerlikowske, Celine Vachon.
